CYBB and peripheral arterial disease: NOX2 has been extensively studied in patients with cardiovascular risk factors and in patients affected by cardiovascular disease [25,26,27], from vascular dysfunction in peripheral artery disease [28], atrial fibrillation [29] and STEMI [30].